Method for predicting and monitoring the efficacy of low-dose IL-2 and hydroxychloroquine therapy in autoimmune diseases and its long-term use in autoimmune-related conditions
A method of inhibiting or treating systemic lupus erythematosus (SLE) and/or primary Sjögren's Syndrome (pSS) in a subject in need thereof is disclosed. The method calls for administering to the subject a therapeutically effective low-dose amount of interleukin-2 and hydroxychloroquine alone or in combination with a therapeutically effective amount of another disease-modifying antirheumatic drug. That combination results in inhibiting or treating SLE and/or pSS in the subject.
